Patent application number | Description | Published |
20090022728 | METHODS OF TREATING OPHTHALMIC DISEASES - Methods of using inhibitors (including monoclonal antibodies) directed against amyloid-beta peptide for the treatment of ophthalmic diseases such as age-related macular degeneration are described. | 01-22-2009 |
20090291897 | METHODS FOR TREATING UNWANTED WEIGHT LOSS OR EATING DISORDERS BY ADMINISTERING A TRKB AGONIST - This invention relates to methods for treating unwanted body weight loss (such as cachexia), eating disorders (such as anorexia nervosa), or opioid-induced emesis by peripheral administration of a trkB agonist. The invention also relates to compositions and kits comprising a trkB agonist. | 11-26-2009 |
20100086997 | TrkB Agonists for Treating Autoimmune Disorders - Tyrosine receptor kinase (TrkB) agonists are provided for reducing leukocyte invasion of the central nervous system in autoimmune diseases such as multiple sclerosis. TrkB agonists include naturally-occurring agonists, such as NT4 and BDNF, as well as agonists such as agonist antibodies. | 04-08-2010 |
20100196390 | AGONIST ANTI-TRKB MONOCLONAL ANTIBODIES - The present invention provides TrkB agonist antibodies. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to improve nerve function, including treatment of peripheral neuropathies, such as Charcot-Marie-Tooth disease. | 08-05-2010 |
20110206698 | ANTAGONIST ANTI-IL-7 RECEPTOR ANTIBODIES AND METHODS - The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus. | 08-25-2011 |
20120148586 | GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONISTS FOR TREATING AUTOIMMUNE DISORDERS - Glucagon-like peptide-1 receptor (GLP-1R) agonists are provided for reducing leukocyte invasion of the central nervous system in autoimmune diseases such as multiple sclerosis. GLP-1R agonists include, e.g., naturally-occurring agonists, such as exendin-4, as well as GLP-1R agonist peptides linked to antibodies. | 06-14-2012 |
20130028916 | ANTAGONIST ANTI-IL-7 RECEPTOR ANTIBODIES AND METHODS - The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus. | 01-31-2013 |
20140141018 | ANTAGONIST ANTI-IL-7 RECEPTOR ANTIBODIES AND METHODS - The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus. | 05-22-2014 |
20140335091 | ANTI-GLUCAGON RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF - The present invention provides antagonizing antibodies that bind to glucagon receptor and methods of using same. The anti-glucagon receptor antibodies can be used therapeutically to lower glucose levels in blood, and can be in the prevention and/or treatment of glucose-related disorders, including diabetes, hyperglycemia, hyperinsulinemia, impaired fasting glucose, impaired glucose tolerance, dyslipidemia, or metabolic syndrome. | 11-13-2014 |
20140356359 | HUMAN GROWTH HORMONE RECEPTOR ANTAGONIST ANTIBODIES AND METHODS OF USE THEREOF - The present invention provides antagonizing antibodies that bind to growth hormone receptor (GHR). The invention further relates to therapeutic methods for use of these antibodies to reduce IGF-1 levels and/or for the treatment and/or prevention of diseases associated with excessive IGF-1, including treatment of acromegaly, gigantism, cancer, diabetic nephropathy, arthritis, and lung inflammation. | 12-04-2014 |
Patent application number | Description | Published |
20080290935 | APPARATUS AND METHOD FOR PREVENTING CURRENT LEAKAGE WHEN A LOW VOLTAGE DOMAIN IS POWERED DOWN - An apparatus and method are provided for preventing a current leakage or direct current when a low voltage domain is powered down. Included is a voltage transition circuit connected between a low voltage domain and a high voltage domain. Such voltage transition circuit includes a circuit component for preventing a current leakage when the low voltage domain is powered down. | 11-27-2008 |
20090045847 | GENERIC FLEXIBLE TIMER DESIGN - One embodiment of the present invention sets forth a set of three building block circuits for designing a flexible timing generator for an integrated circuit. The first and second building blocks include delay elements that may be customized and fine-tuned prior to fabrication. The third building block may be tuned prior to fabrication as well as after fabrication. The three building blocks may be incorporated into a modular architecture, enabling designers to easily generate well-characterized, flexible, generic timer circuits. | 02-19-2009 |
20140056050 | MEMORY CELL AND MEMORY - In various embodiments, a memory cell and a memory are provided. The memory cell comprises a Static Random Access Memory (SRAM) cell including a reset-set (RS) flip-flop and a Read Only Memory (ROM) cell being connected (or coupled) to the SRAM cell to set logic states of internal latch nodes of the RS flip-flop when the ROM cell is triggered. The size of the memory cells proposed in an embodiment of the invention is much smaller than the sum of the size of ROM cells and the size of SRAM cells with the capacity of the memory cells same as the sum of the capacity of the ROM cells and the capacity of the SRAM cells. | 02-27-2014 |
20140125377 | DUAL FLIP-FLOP CIRCUIT - A dual flip-flop circuit combines two or more flip-flip sub-circuits into a single circuit. The flip-flop circuit comprises a first flip-flop sub-circuit and a second flip-flop sub-circuit. The first flip-flop sub-circuit comprises a first storage sub-circuit configured to store a first selected input signal and transfer the first selected input signal to a first output signal when a buffered clock signal transitions between two different logic levels and a dock driver configured to receive a clock input signal, generate an inverted clock signal, and generate the buffered clock signal. The second flip-flop sub-circuit is coupled to the clock driver and configured to receive the inverted clock signal and the buffered clock signal. The second flip-flop sub-circuit comprises a second storage sub-circuit configured to store a second selected input signal and transfer the second selected input signal to a second output signal when the buffered clock signal transitions. | 05-08-2014 |
20140129887 | FLIP-FLOP CIRCUIT HAVING A REDUCED HOLD TIME REQUIREMENT FOR A SCAN INPUT - A scan flip-flop circuit comprises a scan input sub-circuit and a selection sub-circuit. The scan input sub-circuit is configured to receive a scan input signal and a scan enable signal and, when the scan enable signal is activated, generate complementary scan input signals representing the scan input signal that are delayed relative to a transition of a clock input signal between two different logic levels. The selection sub-circuit is coupled to the scan input sub-circuit and configured to receive the complementary scan input signals and, based on the scan enable signal, output an inverted version of either the scan input signal or a data signal as a first selected input signal. | 05-08-2014 |
20140167828 | SMALL AREA LOW POWER DATA RETENTION FLOP - Small area low power data retention flop. In accordance with a first embodiment of the present invention, a circuit includes a master latch coupled to a data retention latch. The data retention latch is configured to operate as a slave latch to the master latch to implement a master-slave flip flop during normal operation. The data retention latch is configured to retain an output value of the master-slave flip flop during a low power data retention mode when the master latch is powered down. A single control input is configured to select between the normal operation and the low power data retention mode. The circuit may be independent of a third latch. | 06-19-2014 |
20140169108 | MITIGATING EXTERNAL INFLUENCES ON LONG SIGNAL LINES - Mitigating external influences on long signal lines. In accordance with an embodiment of the present invention, a column of a memory array includes first and second transistors configured to pull up the bit line of the column. The column includes a third transistor configured to selectively pull up the bit line of the column responsive to a level of the inverted bit line of the column and a fourth transistor configured to selectively pull up the inverted bit line of the column responsive to a level of the bit line of the column. The column further includes fifth and sixth transistors configured to selectively pull up the bit line and inverted bit line of the column responsive to the clamp signal and a seventh transistor configured to selectively couple the bit line of the column and the inverted bit line of the column responsive to the clamp signal. | 06-19-2014 |
20140313817 | SRAM CORE CELL DESIGN WITH WRITE ASSIST - A static random access memory (SRAM) cell is disclosed. The SRAM cell includes a storage unit configured to store a data bit in a storage node. The SRAM cell further includes an access unit coupled to the storage unit. The access unit is configured to transfer current to the storage node when a word line is asserted. The SRAM cell further includes a row header configured to provide current from a power supply when the word line is not asserted, and to not provide current from the power supply when the word line is asserted. The SRAM cell further includes a column header configured to provide current from a power supply when a write column line is not asserted, and to not provide current from the power supply when the write column line is asserted. | 10-23-2014 |
20140347916 | EIGHT TRANSISTOR (8T) WRITE ASSIST STATIC RANDOM ACCESS MEMORY (SRAM) CELL - Disclosed are devices, systems and/or methods relating to an eight transistor (8T) static random access memory (SRAM) cell, according to one or more embodiments. In one embodiment, an SRAM storage cell is disclosed comprising a word line, a write column select line, a cross-coupled data latch, and a first NMOS switch device serially coupled to a second NMOS switch device. In this embodiment, the gate node of the first NMOS switch device is coupled to the word line, a source node of the first NMOS switch device is coupled to the cross-coupled data latch, a gate node of the second NMOS switch device is coupled to the write column select line, and a source node of the second NMOS switch device is coupled to the cross-coupled data latch. | 11-27-2014 |
Patent application number | Description | Published |
20100240542 | KITS FOR MULTIPARAMETRIC PHOSPHO ANALYSIS - As disclosed herein, the present invention provides for kits and a composition for diagnosis, prognosis, drug discovery, drug development, and patient stratification. The kits can comprise a plurality of binding elements for cell surface markers, and a plurality of binding elements for state-specific intracellular markers. The kits can further comprise a plurality of modulators directed for the particular cell function or signaling pathways. The kits can further include fixatives, permeabilizing agent, buffers, containers, instructions, and software for data analysis/compilation. | 09-23-2010 |
20120276558 | KITS FOR MULTIPARAMETRIC PHOSPHO ANALYSIS - As disclosed herein, the present invention provides for kits and a composition for diagnosis, prognosis, drug discovery, drug development, and patient stratification. The kits can comprise a plurality of binding elements for cell surface markers, and a plurality of binding elements for state-specific intracellular markers. The kits can further comprise a plurality of modulators directed for the particular cell function or signaling pathways. The kits can further include fixatives, permeabilizing agent, buffers, containers, instructions, and software for data analysis/compilation. | 11-01-2012 |
20150119288 | KITS FOR MULTIPARAMETRIC PHOSPHO ANALYSIS - As disclosed herein, the present invention provides for kits and a composition for diagnosis, prognosis, drug discovery, drug development, and patient stratification. The kits can comprise a plurality of binding elements for cell surface markers, and a plurality of binding elements for state-specific intracellular markers. The kits can further comprise a plurality of modulators directed for the particular cell function or signaling pathways. The kits can further include fixatives, permeabilizing agent, buffers, containers, instructions, and software for data analysis/compilation. | 04-30-2015 |
Patent application number | Description | Published |
20100080819 | MODULATORS OF P-SELECTIN GLYCOPROTEIN LIGAND 1 - Multimeric compounds that bind to P-Selectin Glycoprotein 1 (PSGL-1) on the surface of T cells or natural killer (NK) cells can be used to induce T cell or NK cell depletion and/or to induce T cell or NK cell apoptosis. The multimeric compounds and methods of the invention can be used to control unwanted T cell- or NK cell-mediated immune responses in conditions such as inflammatory diseases, autoimmune diseases, transplant rejection, and allergic diseases. | 04-01-2010 |
20110172397 | ANTI-PSGL-1 ANTIBODIES - Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject. | 07-14-2011 |
20130011861 | MODULATORS OF P-SELECTIN GLYCOPROTEIN LIGAND 1 - Compounds that bind to P-Selectin Glycoprotein 1 (PSGL-1) on the surface of T cells or natural killer (NK) cells can be used to induce T cell or NK cell depletion and/or to induce T cell or NK cell apoptosis. The compounds and methods of the invention can be used to control unwanted T cell- or NK cell-mediated immune responses in conditions such as autoimmune diseases, transplant rejection, and allergic diseases. | 01-10-2013 |
20130101587 | ANTI-PSGL-1 ANTIBODIES - Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject. | 04-25-2013 |
20130102762 | ANTI-PSGL-1 ANTIBODIES - Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject. | 04-25-2013 |
20140065176 | T-CELL DEATH-INDUCING EPITOPES - Cell death-inducing epitopes and polypeptides containing same. Also disclosed are compounds for inducing death of activated T-cells, a method of producing antibodies to the epitopes, a method of identifying compounds that bind to the epitopes, a method of inducing death of activated T-cells, and pharmaceutical compositions containing the compounds. | 03-06-2014 |
20150183870 | ANTI-PSGL-1 ANTIBODIES - Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject. | 07-02-2015 |
Patent application number | Description | Published |
20100056216 | Techniques utilizing adaptive codebooks for beamforming in wireless networks - An embodiment of the present invention provides a method, comprising using an adaptive codebook for beamforming for communications in wireless networks. | 03-04-2010 |
20110064158 | DIFFERENTIAL FEEDBACK SCHEME FOR CLOSED-LOOP MIMO BEAMFORMING - A first N×M codebook of a first rank M may be used to generate a second N×(N−M) codebook of a second rank (N−M). This second codebook is both orthogonal and complementary to the first codebook. In practice, this may reduce storage requirements in closed-loop MIMO beamforming, because the second codebook may be dynamically generated as needed by a base station and/or a mobile station. In some cases, a higher rank beamforming matrix or precoding matrix may be formed from a lower rank (e.g., one or two) beamforming matrix or precoding matrix. Also, a novel way to generate the rotation matrix Q | 03-17-2011 |
20120069940 | PLATFORM NOISE ESTIMATION AND MITIGATION FOR WIRELESS RECEIVERS - An apparatus and method suitable to estimate impairments of wireless signals, including both noise and interference of the wireless signals are disclosed herein. The noise of the wireless signals may be caused by thermal noise and platform noise. An adaptive scheme may dynamically switch between estimating interference only or the combined noise and interference. Other embodiments may be disclosed or claimed. | 03-22-2012 |
20140286133 | DEVICE-TO-DEVICE ANGLE DETECTION WITH ULTRASOUND AND WIRELESS SIGNAL - A method for determining orientation of an electronic device relative to another electronic device is described. The method includes synchronizing internal clock of a first electronic device with internal clock of a second electronic device using electromagnetic signals communicated between the first electronic device and the second electronic device, sending two or more sound waves from the second electronic device, receiving the two or more sound waves at the first electronic device, and calculating orientation of the first electronic device relative to the second electronic device based on a difference in time of arrival of the two or more sound waves at the first electronic device. The first electronic device and the second electronic device each have at least one transceiver configured to send and receive electromagnetic signals. The first electronic device has two or more acoustoelectric transducers and the second electronic device has one or more acoustoelectric transducer. | 09-25-2014 |
Patent application number | Description | Published |
20080269868 | STENT DELIVERY CATHETER SYSTEM AND METHOD OF IMPLANTING A SELF-EXPANDING STENT WITH EMBOLIC PROTECTION - A catheter system and method for implanting an i such as a stent at a treatment site in a patient's body lumen. The catheter provides a complete system for stent delivery, dilatation, and delivery and/or recovery of an expandable device, such as an embolic protection device, adjacent to the treatment site in the body lumen. | 10-30-2008 |
20090165898 | FATIGUE-RESISTANT NICKEL-TITANIUM ALLOYS AND MEDICAL DEVICES USING SAME - Superelastic and/or shape memory nickel-titanium alloys having an increased fatigue life that is superior to known nickel-titanium alloys are disclosed. The nickel-titanium alloys have a minimum fatigue life that may be at least about 10 million strain cycles at a strain of at least about 0.75. The minimum fatigue life may be due, at least in part, to the nickel-titanium alloy having at least one of an oxygen concentration of less than about 200 ppm, a carbon concentration of less than about 200 ppm, the absence of oxide-based and/or carbide-based inclusions having a size greater than about 5 microns (μm), the presence of an R-phase, or combinations of the foregoing. Articles manufactured from such fatigue-resistant nickel-titanium alloys can be more durable because they are more resistant to repetitive strain and crack propagation. | 07-02-2009 |
20100331951 | STENT DELIVERY CATHETER SYSTEM AND METHOD OF IMPLANTING A SELF-EXPANDING STENT WITH EMBOLIC PROTECTION - A catheter system and method for implanting an endoprosthesis such as a stent at a treatment site in a patient's body lumen. The catheter provides a complete system for stent delivery, dilatation, and delivery and/or recovery of an expandable device, such as an embolic protection device, adjacent to the treatment site in the body lumen. | 12-30-2010 |
20110247943 | SYSTEM AND METHOD FOR ELECTROPOLISING DEVICES - A system and method is described for electropolising tubular metallic prostheses. In one aspect, the system provides a continuously changing set of points of contact between anode and prosthesis. In another aspect, the cathode is given a conical shape to correct for current concentrations that would otherwise exist and unevenly affect the amount of electropolishing over the length of the prosthesis. | 10-13-2011 |
20130205567 | FATIGUE-RESISTANT NICKEL-TITANIUM ALLOYS AND MEDICAL DEVICES USING SAME - Superelastic and/or shape memory nickel-titanium alloys having an increased fatigue life that is superior to known nickel-titanium alloys are disclosed. The nickel-titanium alloys have a minimum fatigue life that may be at least about 10 million strain cycles at a strain greater than about 0.75%. The minimum fatigue life may be due, at least in part, to the nickel-titanium alloy having at least one of an oxygen concentration of less than about 200 ppm, a carbon concentration of less than about 200 ppm, the absence of oxide-based and/or carbide-based inclusions having a size greater than about 5 microns (μm), the presence of an R-phase, or combinations of the foregoing. Articles manufactured from such fatigue-resistant nickel-titanium alloys can be more durable because they are more resistant to repetitive strain and crack propagation. | 08-15-2013 |
20140014530 | METHODS FOR PASSIVATING METALLIC IMPLANTABLE MEDICAL DEVICES INCLUDING RADIOPAQUE MARKERS - The present disclosure is directed to methods of manufacturing and passivating stents and other implantable medical devices including one or more attached radiopaque markers. In one embodiment, the method includes providing a metallic implantable medical device body without any radiopaque marker(s) attached thereto, primary electropolishing the device body without any markers attached thereto, attaching one or more radiopaque markers to the device body, and lightly electropolishing the device including device body and attached radiopaque markers. Light electropolishing removes no more than about 5 percent by weight of the device (i.e., the device body and attached marker(s)). Light electropolishing passivates the exposed surfaces of the device body and markers, while also providing electropolishing to the region of any welds where the radiopaque marker(s) attach to the device body. | 01-16-2014 |
20150196693 | PASSIVATED METALLIC IMPLANTABLE MEDICAL DEVICES INCLUDING RADIOPAQUE MARKERS - The present disclosure is directed to methods of manufacturing and passivating stents and other implantable medical devices including one or more attached radiopaque markers. In one embodiment, the method includes providing a metallic implantable medical device body without any radiopaque marker(s) attached thereto, primary electropolishing the device body without any markers attached thereto, attaching one or more radiopaque markers to the device body, and lightly electropolishing the device including device body and attached radiopaque markers. Light electropolishing removes no more than about 5 percent by weight of the device (i.e., the device body and attached marker(s)). Light electropolishing passivates the exposed surfaces of the device body and markers, while also providing electropolishing to the region of any welds where the radiopaque marker(s) attach to the device body. | 07-16-2015 |